A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Conditions

• Carcinoma, Non-Small Cell Lung

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• erlotinib — DRUG
  plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
• sunitinib — DRUG
  Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
• erlotinib — DRUG
  plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
• placebo — DRUG
  Placebo daily by oral capsules in a continuous regimen

Study Details

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Key Dates

First listed

Apr 6, 2007

Start date

Jul 31, 2007

Status verified

Sep 2013

Primary completion

Jul 31, 2010

Completion

Dec 31, 2012

Study Design

Enrollment

960 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: 1
• Active Comparator: 2

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: Baseline to death or 28 days after last dose for the last participant ]

Locations (63)

Find similar trials in Florence, AL

Related Studies

• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  PHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska
• Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
  PHASE1/PHASE2 · Recruiting · Genprex, Inc. · Los Angeles, California
• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
  PHASE2 · Recruiting · Georgetown University · Washington D.C., District of Columbia
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  PHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland